JOINT AND MUSCLE RESEARCH INSITUTE
Clinical Research Study Opportunities; Exploring Safety and Effectiveness of New Treatments
Are you living with Lupus, Psoriatic Arthritis, Rheumatoid Arthritis, Gout, or Sjogren's Syndrome? We are conducting exciting clinical research studies aimed at testing innovative treatments that may help manage symptoms more effectively, with fewer side effects.
In joining our studies, you will have the opportunity to contribute to advancing medical research and potentially access cutting-edge treatments that could improve the quality of life not only for yourself but others living with these conditions.
Currently Enrolling Studies
AbbVie-Protocol M23-699, Indication: Lupus
Title: SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
AbbVie- Protocol M25-056, Indication: Rheumatoid Arthritis
Title: A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis.
Janssen-Protocol JNJ-77242113PSA3001, Indication: Psoriatic Arthritis
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants with Active Psoriatic Arthritis
Janssen-Protocol JNJ-77242113PSA3002, Indication: Psoriatic Arthritis
Title: A Phase 3, Multicenter, Randomized Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JAN-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis
Janssen-Protocol JNJ-80202135SJS3001, Indication: Sjogren's Disease
Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjögren's Disease (SjD).
Resolve-Protocol RSLV132-06, Indication: Sjogren's Disease
Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Intravenous RSLV-132 in Participants with Sjogren’s Syndrome (SS) with Moderate to Severe Symptom Burden